The Parkinson’s Action Network (PAN) recently received a letter from Dr. Michael Rosenblatt at Merck, the maker of Sinemet. Because of proposed changes with the manufacturing supply source and Merck’s regaining of marketing and distribution rights to Sinemet, there may be temporary supply issues in the United States early this year. Merck is currently working with the Food and Drug Administration to seek approval of the new supply sources for Sinemet. All parties are hopeful that the approval process will be speedy and that no shortage will occur. To keep the Parkinson’s community informed of this issue, PAN has included Merck’s letter below. If you have any questions regarding the letter, please contact us. We will keep you updated of any developments. If you have any questions regarding your personal medical care after reading this letter, please speak with your physician.